SRPT Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of 21.68%. Sarepta Therapeutics's return on equity of -20.94% beat Eli Lilly and's return on equity of 78.25%.

Sarepta Therapeutics has a consensus price target of $47.96, signalling upside risk potential of 163.95%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.08%. Given that Sarepta Therapeutics has higher upside potential than Eli Lilly and, analysts believe Sarepta Therapeutics is more attractive than Eli Lilly and.

Sarepta Therapeutics has a beta of 0.448, which suggesting that the stock is 55.179% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sarepta Therapeutics quarterly revenues are $744.9M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Sarepta Therapeutics's net income of -$447.5M is lower than Eli Lilly and's net income of $2.8B. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Eli Lilly and's PE ratio is 64.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 0.90x versus 14.62x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of -907.48%. Sarepta Therapeutics's return on equity of -20.94% beat Moderna's return on equity of -29.23%.

Sarepta Therapeutics has a consensus price target of $47.96, signalling upside risk potential of 163.95%. On the other hand Moderna has an analysts' consensus of $47.59 which suggests that it could grow by 41.47%. Given that Sarepta Therapeutics has higher upside potential than Moderna, analysts believe Sarepta Therapeutics is more attractive than Moderna.

Sarepta Therapeutics has a beta of 0.448, which suggesting that the stock is 55.179% less volatile than S&P 500. In comparison Moderna has a beta of 1.845, suggesting its more volatile than the S&P 500 by 84.505%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $744.9M, which are larger than Moderna quarterly revenues of $107M. Sarepta Therapeutics's net income of -$447.5M is higher than Moderna's net income of -$971M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 0.90x versus 4.17x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of -7.89%. Sarepta Therapeutics's return on equity of -20.94% beat Supernus Pharmaceuticals's return on equity of 6.24%.

Sarepta Therapeutics has a consensus price target of $47.96, signalling upside risk potential of 163.95%. On the other hand Supernus Pharmaceuticals has an analysts' consensus of $39.00 which suggests that it could grow by 17.75%. Given that Sarepta Therapeutics has higher upside potential than Supernus Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Supernus Pharmaceuticals.

Sarepta Therapeutics has a beta of 0.448, which suggesting that the stock is 55.179% less volatile than S&P 500. In comparison Supernus Pharmaceuticals has a beta of 0.700, suggesting its less volatile than the S&P 500 by 30.01%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. Supernus Pharmaceuticals pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $744.9M, which are larger than Supernus Pharmaceuticals quarterly revenues of $149.8M. Sarepta Therapeutics's net income of -$447.5M is lower than Supernus Pharmaceuticals's net income of -$11.8M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while Supernus Pharmaceuticals's PE ratio is 29.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 0.90x versus 2.78x for Supernus Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of -60.08% compared to Sarepta Therapeutics's net margin of 40.56%. Sarepta Therapeutics's return on equity of -20.94% beat United Therapeutics's return on equity of 19.92%.

Sarepta Therapeutics has a consensus price target of $47.96, signalling upside risk potential of 163.95%. On the other hand United Therapeutics has an analysts' consensus of $377.01 which suggests that it could grow by 27.58%. Given that Sarepta Therapeutics has higher upside potential than United Therapeutics, analysts believe Sarepta Therapeutics is more attractive than United Therapeutics.

Sarepta Therapeutics has a beta of 0.448, which suggesting that the stock is 55.179% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.534, suggesting its less volatile than the S&P 500 by 46.629%.

Sarepta Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sarepta Therapeutics pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

Sarepta Therapeutics quarterly revenues are $744.9M, which are smaller than United Therapeutics quarterly revenues of $794.4M. Sarepta Therapeutics's net income of -$447.5M is lower than United Therapeutics's net income of $322.2M. Notably, Sarepta Therapeutics's price-to-earnings ratio is 20.50x while United Therapeutics's PE ratio is 11.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sarepta Therapeutics is 0.90x versus 4.76x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.